Vigil Neuroscience Inc

NASDAQ VIGL

Data sourced from

and

Daily

Download Data

Vigil Neuroscience Inc Price to Sales Ratio (P/S) on June 03, 2024: 57.13

Vigil Neuroscience Inc Price to Sales Ratio (P/S) is 57.13 on June 03, 2024, a NA change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.

Vigil Neuroscience Inc 52-week high Price to Sales Ratio (P/S) is 73.46 on May 08, 2024, which is 28.57% above the current Price to Sales Ratio (P/S).
Vigil Neuroscience Inc 52-week low Price to Sales Ratio (P/S) is 57.06 on May 06, 2024, which is -0.13% below the current Price to Sales Ratio (P/S).
Vigil Neuroscience Inc average Price to Sales Ratio (P/S) for the last 52 weeks is 65.45.

NASDAQ: VIGL

Vigil Neuroscience Inc

CEO	Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.
IPO Date	Jan. 7, 2022
Location	United States
Headquarters	1 Broadway, Cambridge, MA, United States, 02142
Employees	65
Sector	Healthcare
Industry	Biotechnology

Description

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Key trends